Adenosine A2a Receptor Blockade Before Striatal Excitotoxic Lesions Prevents Long Term Behavioural Disturbances in the Quinolinic Rat Model of Huntington's Disease.
From: Department of Cell Biology and Neuroscience, Istituto Superiore di Sanità , Viale Regina Elena 299, I-00161 Rome, Italy.
Behavioural brain research
- Publish Date: Jan 2007
- ISSN: 0166-4328
- Volume: 176
- Issue: 2
- Pages: 216-21
- Medium: Print
- Language: English
- Citation (JAMA): Scattoni Maria Luisa, Valanzano Angelina, Pezzola Antonella, et al. Adenosine A2a Receptor Blockade Before Striatal Excitotoxic Lesions Prevents Long Term Behavioural Disturbances in the Quinolinic Rat Model of Huntington's Disease.. Behav. Brain Res. Jan 2007;176:216-21
Abstract
Huntington’s disease (HD) is a progressive neurodegenerative disorder, characterised by severe degeneration of basal ganglia, motor abnormalities, impaired cognitive function and emotional disturbances. Many of the distinct neuropathological features of HD are reproduced in rats by intrastriatal injections of the excitotoxin quinolinic acid (QA), and QA-induced excitotoxicity is partially prevented by administration of the A(2A) receptor antagonist prior to the QA injection. In this study, we assessed the neuroprotective effects of the adenosine A(2A) receptor antagonist SCH 58261 on the progressive behavioural alterations reported in the QA rat model of Huntington’s disease. Male rats received i.p. SCH 58261 (0.01mg/kg) or vehicle 20min before a bilateral injection of quinolinic acid (QA, 300nmol/1mul) or its vehicle in the dorsal striatum. Motor activity and anxiety levels were analyzed in an open-field arena and in an elevated plus-maze at 2 weeks, 2 months and 6 months post-lesion. In QA-lesioned rats SCH 58261 prevented alterations of wall rearing behaviour starting from 2 weeks post-lesion while emotional changes (reduced anxiety) were back to control levels by 6 months post-lesion. These findings extend to the behavioural parameters the protective effects of SCH 58261 in the QA model of Huntington’s disease.
Mesh Headings (Keywords): Analysis of Variance, Animals, Behavior, Animal, Behavioral Symptoms, Corpus Striatum, Disease Models, Animal, Drug Interactions, Exploratory Behavior, Huntington Disease, Male, Maze Learning, Neuroprotective Agents, Pyrimidines, Quinolinic Acid, Rats, Rats, Wistar, Receptor, Adenosine A2A, Time Factors, Triazoles
Check for Full Text / PubMed Unique Identifier (PMID): 17123640
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.